Recently, Beijing Gigaceuticals Tech Co., Ltd., which developed the world's leading drug efficacy prediction system (DLEPS, Lingsu system) based on deep learning and genetic fingerprints, announced the completion of the 10 million RMB angel + round of financing from Sangel Capital.

A joint research team of Peking University Xie Zhengwei, Zheng Ruimao, Zhang Ning, and Zhou Hong first constructed a neural network using Simplified Molecular Linear Input Specification (SMILES) chemical encoding as input to predict transcriptome changes measured in L1000 data...

Recently, the team of Xie Zhengwei from the International School of Cancer, Peking University published a paper in the journal Nature Biotechnology, developing a drug efficacy prediction system called Lingsu System (DLEPS), which can predict the effect of compounds in treating diseases through genetic fingerprints and deep learning.

Application of a drug efficacy prediction system (DLEPS, Lingsu system) based on genetic fingerprints and deep learning in innovative drug development.

AI is the best way to break the anti Moore's law in pharmaceutical industry.

When it comes to the pharmaceutical industry, the first thing everyone thinks about is that R&D costs remain high and the rate of return on R&D continues to decrease.

36kr has also been exposed to 「GigaCeuticals」 recently, and is currently focusing on all aspects of the IND.including target discovery, drug design...

Recently, artificial intelligence has become a hot spot in all walks of life. The powerful modeling capabilities of artificial intelligence provide unlimited possibilities for the development of traditional industries, especially the R&D of new drugs...

Dr. Zhengwei Xie is an assistant professor at Peking University and was a joint doctoral student at Peking University and University of California, San Francisco...